
Three kinds of funding, and the three places they surface in a bodily injury file.

Third-party litigation funding rarely appears in a bodily injury file by name, but its effects often do. This post explains the funding types, selected disclosure rules and the file signals adjusters can record.
Third-party litigation funding is money from an outside party, repaid only from a settlement or judgment. The funder is neither a party to the case nor the lawyer. If the case produces nothing, the funder usually recovers nothing.
The U.S. Government Accountability Office described the market in a December 2022 report. It found that federal law does not specifically regulate the industry. It also found that public data on it are limited.
This post uses "litigation funding" for every form of third-party money in a case. "Litigation finance" is the term used for the commercial market, including in Westfleet Advisors' data.
In a bodily injury file, funding can mean three different arrangements. Each one leaves different traces. This post is general information, not legal advice. State rules change, so confirm current law with counsel.
Commercial funders invest in single cases or in portfolios of cases, and some finance law firms directly. The adjuster almost never sees the agreement. In injury work, commercial money can reach the file indirectly, through a plaintiff firm whose caseload is financed. What the adjuster may see is an opponent with the cash to develop the case early and wait.
Consumer funders advance cash to the injured claimant while the claim is open, for living costs or other expenses. Like other third-party funding, the advance is repaid only from a recovery.
Pricing and disclosure rules vary by state. West Virginia's code, for example, caps the annual fee a litigation financier may charge a consumer at 18% of the amount provided.
The third type sits inside the medical specials. A letter of protection (LOP) is an arrangement where a provider treats now and is paid later from the settlement or judgment. Some providers then sell those receivables to a factoring company for cash.
Florida added section 768.0427 in its 2023 amendments. It applies in personal injury and wrongful death actions and defines an LOP broadly. A claimant seeking medical expenses for LOP treatment must disclose the letter, coded itemized bills and the referral source. If the receivable was sold, the factoring company's name and the amount it paid must be disclosed too.
The billing side of LOP treatment has its own analysis. A related post on letters of protection, treatment stacking and billed vs paid covers it in detail.
The most-cited figures come from Westfleet Advisors. Westfleet tracks the U.S. commercial litigation finance market only. Consumer advances and medical receivable funding are not in its numbers.
Two points matter for claims teams. First, the measured market is commercial, so it says little about what reaches a typical auto or general liability file. Second, GAO noted that figures such as funders' returns and total funding provided are not publicly available. Treat any single "injury funding market size" figure with care.
Social inflation is the growth of liability claim costs beyond general economic inflation. Whether litigation funding drives it, and by how much, is debated. Attorney involvement, venue and jury attitudes are also part of that discussion.
The scale of the cost trend is documented. A 2025 analysis by the Insurance Information Institute (Triple-I), an insurance industry group, and the Casualty Actuarial Society measured it. The Triple-I and CAS analysis put the past decade's added liability losses at $231.6 billion to $281.2 billion. It attributed them to what it calls "legal system abuse," not economic inflation alone. It found that severity, not frequency, drives the increase.
Attorney involvement in auto injury claims also grew. The Insurance Research Council studied 7.4 million auto injury claims closed between mid-2017 and mid-2022. Over that window, representation rose from 40% to nearly 50%, and litigation from 10% to 18%. Represented claimants took a median of nearly 440 days to close, more than double the time for unrepresented ones. The data end in mid-2022, so they do not show more recent years.
Neither study isolates funding's share of the increase. Stakeholders interviewed by GAO described both sides. Funding can help underfunded plaintiffs litigate their cases. It is also expensive and may deter plaintiffs from accepting a settlement offer, because they want to cover what they owe the funder. Large jury verdicts belong to the same picture, but they are a separate topic.
For the adjuster, the practical point is narrower. Funding changes the economics on the other side of the file. That can affect timing, demand levels and the documents that arrive.
No national rule requires disclosure of funding. A patchwork of state statutes, federal local rules and judge-specific orders has grown since 2018. The table shows selected examples, not a complete list. Triple-I counts more than 20 states that now regulate litigation funding, Insurance Business reported. Scope, thresholds and effective dates differ, and rules change often, so confirm current law with counsel.
Medical funding has its own rules. Florida's section 768.0427 reaches LOPs and sold receivables, as described above. Georgia's Senate Bill 68 (2025) makes LOP agreements and amounts of receivables sold to third parties relevant and discoverable.
Outside these rules, disclosure depends on the court and the judge. GAO noted that some courts require it, but there is no national requirement.
The agreement is rarely in the file. Its effects often are. The signals below are practical indicators drawn from the document trail, not a validated test. Funding is lawful, and none of them proves funding on its own. Each is a reason to look closer and record what you find.
Consider an illustrative auto claim, not a real case. The claimant has health insurance but treats at a clinic under an LOP. Weeks later, the bills arrive from a company that is not the clinic. After the demand, a lien letter from a funding company follows.
None of this proves anything improper. The adjuster records LOP treatment, the receivable purchaser and the funder lien in structured fields. Defense counsel then checks whether a medical funding statute or disclosure rule applies in the venue.
Tracking works best as structured fields, not notes buried in a diary entry. Consistent fields let a claims leader see patterns across a book, by firm, provider or venue. One file shows little. Many files can show a pattern.
Funding indicators belong in the reserve rationale. A file with LOP treatment and sold receivables can show billed specials far above the amount paid. Whether billed or paid amounts drive damages depends on state law. The reserve note should say which figure was used and why. A related post on reserve accuracy from day one explains why early file review matters here.
These signals sit across many pages: bills, correspondence, lien letters and provider records. amaise's Bodily Injury AI processes the unstructured documents in injury claims and categorizes medical records with ICD-10 coding. Findings stay traceable to the source page, as the agentic AI platform page describes. The software extracts and organizes the documents. The adjuster decides what each signal means.
The file will rarely prove that a case is funded. It can show the structure around the claim: who treated, who is owed, who bought the receivable and when representation began. Those facts are worth recording whether or not funding is ever confirmed.
Third party litigation funding is one possible input to social inflation, not the whole story. Treat it as a set of observable signals, track them in structured fields, and let defense counsel apply the disclosure rules that fit the venue.
No federal law specifically regulates it, according to GAO. States regulate it in different ways, from consumer funding statutes to disclosure rules and limits on funder control. Whether a specific arrangement is permitted is a state-law question for counsel.
Whether and how to ask is a question for defense counsel and company claims-handling guidelines. After suit is filed, disclosure depends on the jurisdiction's statutes, local rules and the judge. Formal requests are best handled through defense counsel.
No. Westfleet Advisors tracks the U.S. commercial litigation finance market. Consumer pre-settlement advances and medical receivable funding are outside those figures.
A letter of protection lets a provider treat now and be paid from the settlement or judgment. When the provider sells that receivable, a third party holds a financial interest in the outcome. Florida and Georgia make details of these arrangements disclosable or discoverable.
Choose which cookies and similar technologies we may use. You can change your choice at any time. Details are in our Cookie Notice.